Have a feature idea you'd love to see implemented?
Let us know!
NERV Minerva Neurosciences Inc
Price (delayed)
$2.68
Market cap
$18.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.45
Enterprise value
-$12.24M
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
Highlights
The EPS is up by 11% year-on-year
The company's quick ratio has shrunk by 73% YoY and by 40% QoQ
The company's net income fell by 26% YoY and by 6% QoQ
Key stats
What are the main financial stats of NERV
Market
Valuations
Earnings
Shares outstanding
6.99M
Market cap
$18.74M
Enterprise value
-$12.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$33.65M
EBITDA
-$33.61M
Free cash flow
-$20.83M
Per share
Balance sheet
Liquidity
EPS
-$4.45
Free cash flow per share
-$2.75
Book value per share
-$6.36
Revenue per share
$0
TBVPS
$4.15
Total assets
$46.29M
Total liabilities
$90.78M
Debt
$0
Equity
-$44.49M
Working capital
$27.21M
Debt to equity
0
Current ratio
7.47
Quick ratio
7.37
Net debt/EBITDA
0.92
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-62.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-79.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NERV stock price
How has the Minerva Neurosciences stock price performed over time
Intraday
3.08%
1 week
-0.74%
1 month
-2.9%
1 year
-58.77%
YTD
-56.42%
QTD
0.37%
Financial performance
How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$26.21M
Net income
-$33.65M
Gross margin
N/A
Net margin
N/A
NERV's operating income is down by 30% year-on-year and by 7% since the previous quarter
The company's net income fell by 26% YoY and by 6% QoQ
Growth
What is Minerva Neurosciences's growth rate over time
Valuation
What is Minerva Neurosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 11% year-on-year
Minerva Neurosciences's equity has decreased by 22% QoQ
Efficiency
How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has decreased by 35% YoY and by 17% QoQ
Dividends
What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NERV.
Financial health
How did Minerva Neurosciences financials performed over time
The total assets is 49% less than the total liabilities
The company's quick ratio has shrunk by 73% YoY and by 40% QoQ
Minerva Neurosciences's current ratio has shrunk by 73% YoY and by 41% QoQ
The debt is 100% more than the equity
Minerva Neurosciences's equity has decreased by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.